| Regulatory science, Pharmaceutical Industry Policy |
2021.04 - 2021.10 |
An analysis of pharmaceutical industry business ecosystem and policy suggestions for new drug development |
Completed |
| RWD/RWE |
2021.03 - 2022.12 |
Clinical characteristics associated with adherence and persistence in patients with type 2 diabetes mellitus treated with dulaglutide |
Completed |
| Machine learning |
2021.02 - 2022.03 |
Development of “KGC curation algorithm" (personalized recommendation of health functional foods)" |
Completed |
| Machine learning, Natural Language Processing |
2021.02 - 2021.12 |
Extration of Comprehensive Drug Safety Information from Adverse Drug Event Narratives in Korean Adverse Event Reporting System (KAERS) |
Completed |
| Machine learning, Natural Language Processing |
2021.02 - 2021.12 |
Development of natural language processing algorithms for extracting key clinical information from text data of drug adverse event reporting |
Completed |
| Pharmacometrics |
2021.01 - 2023.12 |
A population PK model of Vactosertib |
Completed |
| RWD/RWE |
2021.01 - 2022.12 |
Factors affecting the changes in antihypertensive medications in patients with hypertension |
Completed |
| Regulatory science, Pharmaceutical Industry Policy |
2020.06 - 2020.10 |
Policy suggestions to improve patient access to new drugs in Korea |
Completed |
| RWD/RWE |
2020.03 - 2024.03 |
ARWD based retrospective analysis to evaluate efficacy and safety of SGLT2 inhibitors as add-on treatment in patients with type 2 diabetes mellitus on Metformin, Sulfonylurea and/or DPP-4 Inhibitors |
Completed |
| RWD/RWE |
2020.03 - 2023.03 |
A CDM-based clinical trial to evaluate efficacy and safety of SGLT2 inhibitors as add-on treatment in patients with type 2 diabetes mellitus on Metformin, Sulfonylurea, and/or DPP-4 Inhibitors |
Completed |
| RWD/RWE |
2020.03 - 2021.12 |
Effectiveness and safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i) added to mono, dual or triple treatment in patients with type 2 diabetes mellitus (T2DM) |
Completed |
| Pharmacometrics |
2020.01 - 2022.12 |
A population PK–PD model of YH4808, a novel P-CAB, and intragastric pH that incorporated negative feedback by increased intragastric pH onto the systemic exposure to YH4808 |
Completed |
HOME
